March
16 Meeting of the San Francisco Bay Area Chapter of the American Statistical
Association
Speakers: Drew Watson, Michael Crager
and Carl Yoshizawa Genomic Health. Watson is VP
Biostatistics, Data Management and Medical Operations. Michael Crager is a Genomic Health Fellow in Biostatistics and Carl
Yoshizawa is Senior Director, Clinical Biostatistics.
Title: Personalized
Medicine and the Development of Clinically Relevant Genomic Predictors: A Case
Study of the Oncotype DX¨ Breast and Colon Cancer Assays
Time: Tuesday,
16 Mar., 4 - 6 PM light refreshments 4 - 4:30, presentation 4:30 – 6 PM
Location: Genomic Health,
Inc., 101 Galveston Drive, Redwood City, CA 94063 (650) 556-9300
Abstract:
The sequencing of the first draft of the human genome, nearly a
decade ago, has ushered in a new era of personalized medicine. As our knowledge
of the human genome has grown, the range of therapeutic options is expanding.
Similarly, rapid improvements in the performance and affordability of molecular
diagnostics have enabled increasingly precise predictions of an individualÕs
predisposition to disease, risk of disease recurrence and likelihood of
response to therapies. However, the field of personalized medicine brings with
it several new statistical challenges. Consequently, while scientific journals
are replete with genomics studies, few of these studies have successfully
established clinical relevance for key biomarkers of interest.
The presenters will discuss rational approaches to biomarker
discovery (Mike Crager), algorithm development (Drew
Watson) and clinical trial design (Carl Yoshizawa)
based on their experience in the development of the Oncotype
DX Breast and Colon Cancer assays. The Oncotype DX Breast
Cancer test is a multigene diagnostic assay widely
used in standard clinical practice that looks at the genomic profile of a
breast tumor to quantify the likelihood that early-stage, estrogen
receptor-positive, lymph node-negative breast cancer will return, or recur
(distant recurrence), and provide information about a woman's likely benefit
from chemotherapy (commonly used to treat early-stage breast cancer). The
recently commercially released Oncotype DX Colon
Cancer test is the first multigene diagnostic assay
developed for the assessment of risk of recurrence in patients with stage II
colon cancer. Areas of statistical research will be illustrated including gene
identification using true discovery rate degree of association (TDRDA) sets,
algorithm development methodologies and predictiveness
curves for survival data, and prospective cohort sampling designs using banked
tissue samples.
Directions:
From San Francisco Airport via Highway 101 South exit
Woodside/Seaport Blvd/CA-84 and proceed left towards
Seaport Blvd. Merge onto Seaport Blvd. Turn left onto Chesapeake Drive (2nd
traffic signal). Make an immediate left onto Galveston Drive. Make an immediate
left into Genomic Health parking lot.
From San Jose Airport via Highway 101 North exit Woodside/Seaport
Blvd/CA-84 proceed right towards Seaport Blvd. Merge onto Seaport Blvd. Turn
left onto Chesapeake Drive (2nd traffic signal). Make an immediate left onto
Galveston Drive. Make an immediate left into Genomic Health parking lot.
From Interstate 280 North or South exit Woodside Road East. After
approx. 4 miles Woodside Road will turn into Seaport Blvd when you go under the
Hwy 101 overpass. Turn left onto Chesapeake Drive (2nd traffic signal after Hwy
101 overpass). Make an immediate left onto Galveston Drive. Make an immediate
left into Genomic Health parking lot.
Parking will be across the street from location of the meeting The address is 301 Chesapeake Drive. There will be signs on
where to park and there will be a person from our facilities department to
direct the attendees to park and where to go for the meeting. Being that the
meeting will be during office hours, parking will be limited at
the 101 Penobscot office (where the meeting will be held at).
Return to Bay Area ASA Homepage